Common CLL Symptoms May Include:

- Fatigue
- Unintentional weight loss
- Fever and/or chills
- Night sweats
- Enlarged spleen and/or lymph nodes

High-Risk Biomarkers for CLL Include:

- 11q Deletion
- 17p Deletion
- TP53 Mutation

Supportive Care Team Members

- **Oncology Psychologist or Psychiatrist**: Professionals that provide emotional and supportive care and are specially trained in using behavioral approaches and medications to support patients facing cancer, cancer treatment, and cancer survivorship.

- **Oncology Social Worker**: Licensed professionals who counsel people affected by cancer, providing emotional support and helping people access practical care.

- **Patient Navigator**: Staff members that help navigate the healthcare system, by assessing and addressing immediate needs, and help to plan and provide resources for ongoing support.

Glossary Terms

**Flow Cytometry**: Analyzes your blood and bone marrow cells in order to classify the cell types and determine your disease risk as well as appropriate treatment plan.

**IGHV Mutation**: CLL patients with mutated IGHV may have a longer time to treatment and can have different responses and duration of responses specific to chemotherapy.

**MRD (Minimal Residual Disease)**: Measurement of the number of CLL cells found in the bone marrow of patients in remission after a clinical response to treatment. MRD is relevant as the residual CLL cells may indicate progression or relapse.

**Richter's Transformation**: A rare complication of CLL, in which the disease rapidly transforms into a more aggressive type of lymphoma, such as diffuse large B-cell lymphoma (DLBCL).

CLL Educational Resources

- CancerGRACE | cancergrace.org
- Cancer Support Community (CSC) | cancersupportcommunity.org
- Leukemia Research Foundation | leukemiarf.org
- National Organization for Rare Disorders (NORD) | rarediseases.org
- Twist Out Cancer | twistoutcancer.org

Thrive CLL is brought to you by the Patient Empowerment Network. Funding is provided by an unrestricted educational grant from Pharmacyclics, an AbbVie Company, and Janssen Biotech, Inc.